Zhuomin Liang
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
PCBP1 regulates alternative splicing of AARS2 in congenital cardiomyopathy.
Journal: Nature cardiovascular research
Published: November 06, 2024
Trbp inhibits cardiac fibrosis through TGF-β pathway-mediated cross-talk between cardiomyocytes and fibroblasts.
Journal: Clinical science (London, England : 1979)
Published: October 04, 2024
Therapeutic Inhibition of LincRNA-p21 Protects Against Cardiac Hypertrophy.
Journal: Circulation research
Published: June 12, 2024
PCBP1 regulates alternative splicing of AARS2 in congenital cardiomyopathy.
Journal: bioRxiv : the preprint server for biology
Published: June 09, 2023
The long noncoding RNA CARDINAL attenuates cardiac hypertrophy by modulating protein translation.
Journal: The Journal of clinical investigation
Published: January 25, 2023
Identification of a long noncoding RNA Gm17501 as a novel negative regulator of cardiac hypertrophy.
Identification of a long noncoding RNA Gm17501 as a novel negative regulator of cardiac hypertrophy.
Journal: Experimental cell research
Published: February 15, 2022
Transcribed Ultraconserved Regions, Uc.323, Ameliorates Cardiac Hypertrophy by Regulating the Transcription of CPT1b (Carnitine Palmitoyl transferase 1b).
Journal: Hypertension (Dallas, Tex. : 1979)
Published: November 19, 2019
Maf1 ameliorates cardiac hypertrophy by inhibiting RNA polymerase III through ERK1/2.
Journal: Theranostics
Published: January 10, 2019
Fisetin inhibits cardiac hypertrophy by suppressing oxidative stress.
Journal: The Journal of nutritional biochemistry
Published: March 25, 2018
Showing 1-9 of 9
Last Updated: 09/26/2026